| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vivo |
NY0123 (10 mg/kg; intraperitoneal injection; every two days; for 14 days) significantly inhibited the growth, angiogenesis and cell proliferation of triple-negative breast cancer tumors in BALB/c mice, and its efficacy was superior to ESI-09, and no organ toxicity was observed [1]. NY0123 (25-100 μM; applied topically to the chorioallantoic membrane; single administration; incubation for 48 hours) significantly inhibited angiogenesis in a chicken embryo chorioallantoic membrane model, and its efficacy was superior to ESI-09 [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 5-6 weeks old, 4T1 cell xenograft model) [1]
Doses: 10 mg/kg Route of Administration: Intraperitoneal injection; every two days; for 14 days Experimental Results: Compared with the DMSO control group, tumor volume and tumor weight were significantly reduced. Compared with the DMSO control group, tumor microvessel density (measured by CD31 immunohistochemical staining) and tumor cell proliferation index (measured by Ki67 immunohistochemical staining) were significantly reduced. The inhibitory effect on tumor volume, tumor weight, microvessel density and proliferation index was stronger than that of ESI-09. No treatment-related organ toxicity was found by H&E staining of heart, liver, lung, brain, spleen, kidney and intestinal tissues. Animal/Disease Models:White Leghorn chicken (7-day-old embryo, chorioallantoic membrane vascularization model) [1] Doses: 25 μM, 50 μM, 100 μM Route of Administration:Topical application to the chorioallantoic membrane; single administration; incubation for 48 hours Experimental Experimental Results:Compared with the DMSO control group, the microvascular density of the chorioallantoic membrane was significantly reduced at a concentration of 100 μM. The inhibitory effect on angiogenesis at a concentration of 100 μM was stronger than that of ESI-09 at the same concentration. |
| References |
| Molecular Formula |
C16H13CL3N4O2
|
|---|---|
| Molecular Weight |
399.66
|
| CAS # |
1801911-70-5
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
N#CC(=NNC1=CC(Cl)=C(Cl)C(Cl)=C1)C(=O)C2=NOC(=C2)C(C)(C)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5021 mL | 12.5106 mL | 25.0213 mL | |
| 5 mM | 0.5004 mL | 2.5021 mL | 5.0043 mL | |
| 10 mM | 0.2502 mL | 1.2511 mL | 2.5021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
